Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer

Cancer Biology and Therapy

Volumn 14, Issue 11, 2013, Pages 1016-1023

  Zhu, Wei ^a   Zhang, Hongwei ^a   Shi, Yi ^a   Song, Mangen ^a   Zhu, Bijun ^a   Wei, Lai ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC ADENOVIRUS; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; IN VIVO STUDY; ONCOLYTIC VIROTHERAPY; TRIPLE NEGATIVE BREAST CANCER; VIRUS LOAD; WESTERN BLOTTING;

ADENOVIRUS; TRIPLE-NEGATIVE BREAST CANCER (TNBC); TUMOR NECROSIS FACTOR-RELATED APOPTOSIS INDUCING LIGAND (TRAIL); VIROTHERAPY;

ADENOVIRIDAE; APOPTOSIS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; NEOPLASM METASTASIS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84885971231     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.26043     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi.org/ 10.3322/caac.20107
2. Griffiths CL, Olin JL. Triple negative breast cancer: a brief review of its characteristics and treatment options. J Pharm Pract 2012; 25:319-23; PMID:22551559; http://dx.doi.org/10.1177/0897190012442062
3. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007; 109:1721-8; PMID:17387718; http://dx.doi.org/10.1002/cncr.22618
4. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281:1305-8; PMID:9721089; http://dx.doi.org/10.1126/science.281.5381.1305
5. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH, Walczak H. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000; 12:599-609; PMID:10894160; http://dx.doi.org/10.1016/S1074-7613(00)80211-3
6. Pollack IF, Erff M, Ashkenazi A. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res 2001; 7:1362-9; PMID:11350907
7. Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 1999; 13:1817-24; PMID:10557057; http://dx.doi.org/10.1038/sj. leu.2401501
8. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2:420-30; PMID:12189384; http://dx.doi.org/10.1038/nrc821
9. Galligan L, Longley DB, McEwan M, Wilson TR, McLaughlin K, Johnston PG. Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther 2005; 4:2026-36; PMID:16373718; http://dx.doi.org/10.1158/1535-7163.MCT-05-0262
10. Baritaki S, Huerta-Yepez S, Sakai T, Spandidos DA, Bonavida B. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther 2007; 6:1387-99; PMID:17431117; http://dx.doi.org/10.1158/1535-7163.MCT-06-0521
11. Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, Okumura K. Involvement of tumor necrosis factorrelated apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001; 7:94-100; PMID:11135622; http://dx.doi.org/10.1038/ 83416
12. Khaider NG, Lane D, Matte I, Rancourt C, Piché A. Targeted ovarian cancer treatment: the TRAILs of resistance. Am J Cancer Res 2012; 2:75-92; PMID:22206047
13. Short JJ, Curiel DT. Oncolytic adenoviruses targeted to cancer stem cells. Mol Cancer Ther 2009; 8:2096-102; PMID:19671759; http://dx.doi.org/10. 1158/1535-7163.MCT-09-0367
14. Wong HH, Lemoine NR, Wang Y. Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles. Viruses 2010; 2:78-106; PMID:20543907; http://dx.doi.org/10.3390/v2010078
15. Liu XY, Gu JF. Targeting gene-virotherapy of cancer. Cell Res 2006; 16:740; PMID:16915293; http://dx.doi.org/10.1038/sj.cr.7310088
16. Hardcastle J, Kurozumi K, Chiocca EA, Kaur B. Oncolytic viruses driven by tumor-specific promoters. Curr Cancer Drug Targets 2007; 7:181-9; PMID:17346110; http://dx.doi.org/10.2174/156800907780058880
17. Lu Y. Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer. Adv Drug Deliv Rev 2009; 61:572-88; PMID:19393705; http://dx.doi.org/10.1016/j.addr.2009.03.014
18. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004; 10:5299-312; PMID:15328165; http://dx.doi.org/10.1158/1078-0432.CCR-0349-03
19. Wang W, Jin B, Li W, Xu CX, Cui FA, Liu B, Yan YF, Liu XX, Wang XL. Targeted antitumor effect induced by hTERT promoter mediated ODC antisense adenovirus. Mol Biol Rep 2010; 37:3239-47; PMID:19876766; http://dx.doi.org/10. 1007/s11033-009-9908-5
20. Kojima T, Watanabe Y, Hashimoto Y, Kuroda S, Yamasaki Y, Yano S, Ouchi M, Tazawa H, Uno F, Kagawa S, et al. In vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy. Ann Surg 2010; 251:1079-86; PMID:20485131; http://dx.doi.org/10. 1097/SLA.0b013e3181deb69d
21. Binley K, Askham Z, Martin L, Spearman H, Day D, Kingsman S, Naylor S. Hypoxia-mediated tumour targeting. Gene Ther 2003; 10:540-9; PMID:12646859; http://dx.doi.org/10.1038/sj.gt.3301944
22. Zhang Q, Chen G, Peng L, Wang X, Yang Y, Liu C, Shi W, Su C, Wu H, Liu X, et al. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Clin Cancer Res 2006; 12:6523-31; PMID:17085667; http://dx.doi.org/10.1158/1078-0432.CCR-06-1491
23. Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG, et al. The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl) 2010; 4:35-41; PMID:20697531
24. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL induced apoptosis in breast cell lines. Cancer Res 1999; 59:734-41; PMID:9973225
25. Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, Meltzer PS, Lipkowitz S. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat 2009; 113:217-30; PMID:18266105; http://dx.doi.org/10.1007/s10549-008-9924-5
26. Rakha EA, Chan S. Metastatic triple-negative breast cancer. Clin Oncol (R Coll Radiol) 2011; 23:587-600; PMID:21524569; http://dx.doi.org/10.1016/j.clon. 2011.03.013
27. Rahman M, Pumphrey JG, Lipkowitz S. The TRAIL to targeted therapy of breast cancer. Adv Cancer Res 2009; 103:43-73; PMID:19854352; http://dx.doi.org/10.1016/S0065-230X(09)03003-6
28. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104:155-62; PMID:10411544; http://dx.doi.org/10.1172/JCI6926
29. Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL, Ross BD, Rehemtulla A. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A 2000; 97:1754-9; PMID:10677530; http://dx.doi.org/10.1073/ pnas.030545097
30. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factorrelated apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001; 299:31-8; PMID:11561060
31. Marini P, Schmid A, Jendrossek V, Faltin H, Daniel PT, Budach W, Belka C. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer 2005; 5:5; PMID:15651986; http://dx.doi.org/10.1186/1471- 2407-5-5
32. Griffith TS, Broghammer EL. Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol Ther 2001; 4:257-66; PMID:11545617; http://dx.doi.org/10.1006/mthe.2001.0439
33. Armeanu S, Lauer UM, Smirnow I, Schenk M, Weiss TS, Gregor M, Bitzer M. Adenoviral gene transfer of tumor necrosis factor-related apoptosisinducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res 2003; 63:2369-72; PMID:12750253
34. Dong F, Wang L, Davis JJ, Hu W, Zhang L, Guo W, Teraishi F, Ji L, Fang B. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha- related apoptosis-inducing ligand-armed oncolytic adenovirus. Clin Cancer Res 2006; 12:5224-30; PMID:16951242; http://dx.doi.org/10.1158/1078- 0432.CCR-06-0244
35. Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA, Curley SA, Stephens LC, Fang B. Antitumor activity and bystander effects of the tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001; 61:3330-8; PMID:11309289
36. Kock N, Kasmieh R, Weissleder R, Shah K. Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. Neoplasia 2007; 9:435-42; PMID:17534449; http://dx.doi.org/10.1593/neo.07223
37. Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, Engebraaten O. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. J Gene Med 2007; 9:440-51; PMID:17410615; http://dx.doi.org/10.1002/jgm.1036
38. Wenger T, Mattern J, Haas TL, Sprick MR, Walczak H, Debatin KM, Büchler MW, Herr I. Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects. Cancer Gene Ther 2007; 14:316-26; PMID:17186015; http://dx.doi.org/10.1038/sj.cgt.7701016
39. Zhang Y, Ma H, Zhang J, Liu S, Liu Y, Zheng D. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice. Life Sci 2008; 82:1154-61; PMID:18485417; http://dx.doi.org/10. 1016/j.lfs.2008.03.023
40. Wei N, Fan JK, Gu JF, Liu XY. Double-regulated oncolytic adenovirus-mediated interleukin-24 overexpression exhibits potent antitumor activity on gastric adenocarcinoma. Hum Gene Ther 2010; 21:855-64; PMID:20163249; http://dx.doi.org/10.1089/hum.2009.207
41. de Boer M, van Deurzen CH, van Dijck JA, Borm GF, van Diest PJ, Adang EM, Nortier JW, Rutgers EJ, Seynaeve C, Menke-Pluymers MB, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 2009; 361:653-63; PMID:19675329; http://dx.doi.org/10.1056/NEJMoa0904832
42. Zhu W, Wei L, Zhang H, Chen J, Qin X. Oncolytic adenovirus armed with IL-24 inhibits the growth of breast cancer in vitro and in vivo. Journal of experimental & clinical cancer research. CR (East Lansing, Mich) 2012; 31:51